1. Home
  2. FNLC vs OBIO Comparison

FNLC vs OBIO Comparison

Compare FNLC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

N/A

Current Price

$36.49

Market Cap

415.5M

Sector

Finance

ML Signal

N/A

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

N/A

Current Price

$5.62

Market Cap

362.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FNLC
OBIO
Founded
1864
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
415.5M
362.4M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
FNLC
OBIO
Price
$36.49
$5.62
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $12.43
AVG Volume (30 Days)
33.6K
★ 305.0K
Earning Date
10-21-2026
11-13-2026
Dividend Yield
★ 4.13%
N/A
EPS Growth
26.34
★ 33.13
EPS
★ 1.65
N/A
Revenue
N/A
★ $33,482,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.45
P/E Ratio
$22.43
★ N/A
Revenue Growth
N/A
★ 1169.22
52 Week Low
$24.63
$3.46
52 Week High
$37.50
$6.50

Technical Indicators

Market Signals
Indicator
FNLC
OBIO
Relative Strength Index (RSI) 68.52 51.62
Support Level $34.28 $5.71
Resistance Level N/A $6.38
Average True Range (ATR) 0.95 0.32
MACD 0.24 0.00
Stochastic Oscillator 88.47 57.50

Price Performance

Historical Comparison
FNLC
OBIO

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: